Literature DB >> 15324617

Transcatheter Closure of Intracardiac Shunts.

David T. Balzer1.   

Abstract

Intracardiac shunts, such as atrial septal defects (ASDs), patent foramen ovales (PFOs), and ventricular septal defects (VSDs), are common forms of congenital or acquired heart disease. Traditional treatment has consisted of surgical closure. Transcatheter closure using implantable devices is now an alternative approach to the treatment of these lesions. Transcatheter closure offers advantages over surgical closure: 1) it is less invasive, resulting in shorter recovery times, less hospital time, and no scarring; 2) it avoids the deleterious neurocognitive effects of cardiopulmonary bypass; 3) it avoids the proarrhythmic effects of atrial or ventricular incisions; and 4) it is potentially less costly. Device closure of secundum ASDs is the procedure of choice. Device closure of PFOs can be performed under humanitarian device exemption (HDE) guidelines, although the indications for this procedure and its effectiveness compared with medical management remain controversial. Ongoing studies are addressing these issues. Transcatheter closure of muscular VSDs is an alternative to surgical treatment, especially for apical defects or those anterior to the moderator band. The CardioSEAL device (NMT Medical, Boston, MA) has HDE status for this purpose and the Amplatzer muscular VSD device (AGA Medical Corp., Golden Valley, MN) is being reviewed by the US Food and Drug Administration for market approval. Phase 1 investigations are underway for device closure of perimembranous VSDs using the Amplatzer perimembranous VSD device (AGA Medical Corp.). Until more data are available, surgical closure of perimembranous VSDs is still the procedure of choice. Closure of postinfarct VSDs can also be accomplished using intracardiac devices; however, this remains a high-risk procedure. Early experience compares favorably with surgical closure. Transcatheter device closure of intracardiac defects is a relatively new procedure. Long-term data for these procedures are currently lacking and, therefore, recommendations regarding the use of these devices will continue to evolve with time.

Entities:  

Year:  2004        PMID: 15324617     DOI: 10.1007/s11936-004-0025-4

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  24 in total

1.  Percutaneous closure of postmyocardial infarction ventricular septal defect with the CardioSEAL septal occluder implant.

Authors:  P Pienvichit; T C Piemonte
Journal:  Catheter Cardiovasc Interv       Date:  2001-12       Impact factor: 2.692

2.  Contemporary management of patent foramen ovale.

Authors:  Bernhard Meier; James E Lock
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

Review 3.  Device closure of ventricular septal defects.

Authors:  Ziyad M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2003-09       Impact factor: 2.692

4.  Secundum atrial septal defect. Nonoperative closure during cardiac catheterization.

Authors:  T D King; S L Thompson; C Steiner; N L Mills
Journal:  JAMA       Date:  1976-06-07       Impact factor: 56.272

5.  Cohort study of multiple brain lesions in sport divers: role of a patent foramen ovale.

Authors:  M Knauth; S Ries; S Pohimann; T Kerby; M Forsting; M Daffertshofer; M Hennerici; K Sartor
Journal:  BMJ       Date:  1997-03-08

6.  Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators.

Authors:  B S Crenshaw; C B Granger; Y Birnbaum; K S Pieper; D C Morris; N S Kleiman; A Vahanian; R M Califf; E J Topol
Journal:  Circulation       Date:  2000 Jan 4-11       Impact factor: 29.690

Review 7.  Surgically remediable complications of myocardial infarction.

Authors:  A C Fox; E Glassman; O W Isom
Journal:  Prog Cardiovasc Dis       Date:  1979 May-Jun       Impact factor: 8.194

8.  Transcatheter closure as standard treatment for most interatrial defects: experience in 200 patients treated with the Amplatzer Septal Occluder.

Authors:  F Berger; P Ewert; P G Björnstad; I Dähnert; G Krings; I Brilla-Austenat; M Vogel; P E Lange
Journal:  Cardiol Young       Date:  1999-09       Impact factor: 1.093

9.  Transcatheter closure of post-myocardial infarction ventricular septal defect with Amplatzer septal occluder.

Authors:  A S Mullasari; C V Umesan; U Krishnan; S Srinivasan; M Ravikumar; H Raghuraman
Journal:  Catheter Cardiovasc Interv       Date:  2001-12       Impact factor: 2.692

10.  Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm.

Authors:  C Lamy; C Giannesini; M Zuber; C Arquizan; J F Meder; D Trystram; J Coste; J L Mas
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

View more
  2 in total

1.  Progressive anatomical closure of foramen ovale in normal neonatal mouse hearts.

Authors:  Colleen T Cole-Jeffrey; Ryota Terada; Matthew R Neth; Andy Wessels; Hideko Kasahara
Journal:  Anat Rec (Hoboken)       Date:  2012-02-21       Impact factor: 2.064

2.  Investigation of association between PFO complicated by cryptogenic stroke and a common variant of the cardiac transcription factor GATA4.

Authors:  Mahdi Moradi Marjaneh; Edwin P Kirk; Maximilian G Posch; Cemil Ozcelik; Felix Berger; Roland Hetzer; Robyn Otway; Tanya L Butler; Gillian M Blue; Lyn R Griffiths; Diane Fatkin; Jeremy J Martinson; David S Winlaw; Michael P Feneley; Richard P Harvey
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.